Rocha-de-Lossada, Carlos, Alba Linero, Carmen, Santos Ortega, Alvaro, Rodriguez Calvo-de-Mora, Marina, Rachwani, Rahul, Borroni, Davide 
ORCID: 0000-0001-6952-5647, Alba, Emilio, Benavides Orgaz, Manuel and Romano, Vito ORCID: 0000-0002-5148-7643
(2022)
Ocular surface toxicity of depatuxizumab mafoditin (ABT-414): case reports.
ARQUIVOS BRASILEIROS DE OFTALMOLOGIA, 85 (4).
pp. 411-414.
Abstract
The purpose of this study is to report the clinical features and outcomes of ocular surface toxicity following depatuxizumab mafoditin (ABT-414) therapy for unresectable glioblastoma. Ocular signs and symptoms of three patients treated with ABT-414 during a phase III trial for glioblastoma multiforme were evaluated. Both eyes of all patients were damaged during the week after the first infusion of the ABT-414 molecule. In all patients, mild-to-moderate keratitis could be ascertained, along with decreased visual acuity and blurred vision, as well as foreign-body sensation and redness. Symptoms and visual acuity improved 4 weeks. In conclusion, ABT-414 therapy may cause transient ocular surface toxicity. The initiation of artificial tears and lubricant ointment was enough to control the ocular surface signs and symptoms. A multidisciplinary approach, complete ophthalmologic monitorization, and elaboration of protocols are required to adequately manage these patients.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Glioblastoma/drug therapy, Antibodies, monoclonal, humanized/therapeutic use, Cornea/drug effects, Visual disorders/etiology, Humans, Case reports |
| Divisions: | Faculty of Health and Life Sciences Faculty of Health and Life Sciences > Institute of Life Courses and Medical Sciences |
| Depositing User: | Symplectic Admin |
| Date Deposited: | 31 Jan 2023 10:38 |
| Last Modified: | 15 Mar 2024 12:47 |
| DOI: | 10.5935/0004-2749.2022-0039 |
| Open Access URL: | http://10.0.23.47/0004-2749.20220039 |
| Related URLs: | |
| URI: | https://livrepository.liverpool.ac.uk/id/eprint/3168005 |
Dimensions
Dimensions
